Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"

University Hospital Tuebingen1,350 enrolled

Overview

The GENOME FIRST APPROACH project will enroll patients (n = 450) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and the healthy parents of those affected for trio analysis (N in total 1350).

In the GENOME FIRST APPROACH (monocentric, prospective, open-label diagnostic) project, patients with molecularly undiagnosed diseases will diagnostically be analyzed by Whole Genome Sequencing (WGS)-trio analysis. The following questions will be leading the project: Primary: • Efficacy of WGS trio analysis in different clinical indications Secondary: * Systematically benchmark WGS analysis to detect genetic variations compared to WES and single nucleotide polymorphism (SNP) array analysis, * Expand the analysis from coding single-nucleotide variants (SNVs) to regulatory mutations, structural variants (SVs), and low complexity regions, * Validate the efficacy of clinical genome trio sequencing in a routine diagnostic setting, * Analyse whether 42x coverage has the potential to discover mosaicism as disease causing mechanism, * Further develop algorithms for integrative analyses of Trio-WGS data with Ribonucleic acid- sequencing (RNA-seq), * Identify de novo alterations and novel disease mechanisms, * Gain fundamental new insights into disease mechanisms and cellular biology, * Combine WGS with further Omics methods to improve genetic diagnostics of future rare disease patients, and * Explore overall financial costs and time to report conclusive data to the patients of the Trio-WGS approach compared to traditional multistep diagnostic approaches using single-gene, panel, whole-exome sequencing (WES) and chromosomal microarray (CMA) (SNP array, array-based comparative genomic hybridization (arrayCGH)) analysis. In addition, healthy parents of the subjects will be included in the project to perform parent-child (trio) analyzes.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

1,350

Conditions

Rare Diseases Genetic Predisposition

Interventions

WGS-DiagnosticGENETIC

Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Unclear molecular cause of the disease * Suspected genetic cause of the disease * Healthy parents of those affected for trio analysis Cohort 1: IQ \< 70 with and without malformations, syndromic and non-syndromic Cohort 2: Retinitis pigmentosa, achromatopsy, Bardet-Biedl syndrome, Usher syndrome, congenital stationary night blindness, LCA, macula degeneration, rod/ cone dystrophies, opticus atrophy Cohort 3: Rare paediatric solid cancers as melanoma, carcinoma of the gastrointestinal tract, tumours of the salivary gland and pancreatic tumors in children. Exclusion Criteria: Cohort 1: Toxic causes (drugs, infections) Cohort 2: patients with non-genetic forms of blindness Cohort 3: adult cancer, blood cancer * Missing informed consent of the patient/ legal guardian * Missing samples of both parents * Previous WES or panel analysis-

Locations (1)

University Hospital Tübingen

Tübingen, Germany

Outcomes

Primary Outcomes

Full genomic sequence analysis carried out by Whole Genome Sequencing (WGS)

Number of genomic variants in disease and health parents by WGS (a Next-Generation Sequencing Technology, NGS)

Time frame: Day 1

Secondary Outcomes

Genome sequencing

Verification of the genetic causes of unclear genetic diseases by clinical genome sequencing

Time frame: Day 1

De novo alterations

Number of de novo alterations in genome of the enrolled population

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.